RxDoctor Payments Data

Mark Figgie

New York, NYNPI 1811910953

Payments from drug & device makers

What this record shows

This record is dominated by other: $156,161 of the $221,457 with a category attached, or 70.5%. Encore Medical, LP accounts for 70.5% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2021 at $176,807 and has fallen 99.5% since, to $882 in 2025.

$221,457in general payments, 2019–2025

Across 61 payments — averaging $3630.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Encore Medical, LP$156K
  • Limacorporate S.p.a.$39K
  • Lima USA, Inc.$16K
  • Wishbone Medical Inc.$10K
  • Suvon Surgical LLC$515
  • Zimmer Biomet$170
  • plus $517 from 11 others

What the payments were for

  • Consulting fees$57,76626%
  • Travel & lodging$4,3322%
  • Food & beverage$3,1981%
  • Other$156,16171%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Sodium18$400
Amoxicillin63$157
Clindamycin Hcl11$37

Paid to pharmacies, not to this prescriber.

Where these figures come from

Is this you, or does something look wrong? →